Clinical trial
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide…
NCT00001705 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001705 |
|---|---|
| Title | Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence |
| Official title | Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | GP100 peptide, IL-2 |
| Enrollment | 141 |
| Start date | Jul 1, 1998 |
| Completion | Jun 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: